Evidence map›Paper›PMID 25694335›Full record

ArticleStem cells (Dayton, Ohio)2015

Brief report: isogenic induced pluripotent stem cell lines from an adult with mosaic down syndrome model accelerated neuronal ageing and neurodegeneration.

Aoife Murray, Audrey Letourneau, Claudia Canzonetta, Elisavet Stathaki, Stefania Gimelli, Frederique Sloan-Bena, Robert Abrehart, Pollyanna Goh, Shuhui Lim, Chiara Baldo and 12 more

Open access · hybridAbstract read
In one paragraph

Article in Stem cells (Dayton, Ohio), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers.

0numbers the graph read from it
0cells of the map it votes in
52citing papers in PubMed
3.3field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

52 citing papers in PubMed, 80 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Role of cystathionine-β-synthase and hydrogen sulfide in down syndrome.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2025
    Review
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Transcriptional consequences of trisomy 21 on neural induction.Frontiers in cellular neuroscience · 2024
    Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 10 institutions in 5 countries.

Aoife MurrayThe Blizard Institute, Barts and The London School of Medicine, London, United Kingdom.
Audrey LetourneauDepartment of Genetic Medicine and Development, University of Geneva Medical School, Geneva, Switzerland.
Claudia CanzonettaThe Blizard Institute, Barts and The London School of Medicine, London, United Kingdom.
Elisavet StathakiService of Genetic Medicine, University Geneva Hospitals, Geneva, Switzerland.
Stefania GimelliService of Genetic Medicine, University Geneva Hospitals, Geneva, Switzerland.
Frederique Sloan-BenaService of Genetic Medicine, University Geneva Hospitals, Geneva, Switzerland.
Robert AbrehartThe Blizard Institute, Barts and The London School of Medicine, London, United Kingdom.
Pollyanna GohThe Blizard Institute, Barts and The London School of Medicine, London, United Kingdom.
Shuhui LimLee Kong Chian School of Medicine, Nanyang Technological University, Singapore, Singapore.
Chiara BaldoHuman Genetics Laboratory, Galliera Hospital, Genoa, Italy.
Franca Dagna-BricarelliLiguria Department of Genetics, Genoa, Italy.
Saad HannanDepartment of Neuroscience, Physiology and Pharmacology, University College London, London, United Kingdom.
Martin MortensenDepartment of Neuroscience, Physiology and Pharmacology, University College London, London, United Kingdom.
David BallardDepartment of Forensic and Analytical Science, King's College, London, United Kingdom.
Denise Syndercombe CourtDepartment of Forensic and Analytical Science, King's College, London, United Kingdom.
Noemi FusakiPrecursory Research for Embryonic Science and Technology, Japan Science and Technology Agency, Saitama, Japan.
Mamoru HasegawaDNAVEC Corporation, Ibaraki, Tokyo, Japan.
Trevor G SmartDepartment of Neuroscience, Physiology and Pharmacology, University College London, London, United Kingdom.
Cleo BishopThe Blizard Institute, Barts and The London School of Medicine, London, United Kingdom.
Stylianos E AntonarakisDepartment of Genetic Medicine and Development, University of Geneva Medical School, Geneva, Switzerland.
Jürgen GroetThe Blizard Institute, Barts and The London School of Medicine, London, United Kingdom.
Dean NizeticThe Blizard Institute, Barts and The London School of Medicine, London, United Kingdom.
Wellcome Trust · GBQueen Mary University of London · GBUniversity College London · GBUniversity Hospital of Geneva · CHKing's College London · GBUniversity of Geneva · CHEnte Ospedaliero Ospedali Galliera · ITID Pharma (Japan) · JPJapan Science and Technology Agency · JPNanyang Technological University · SG

Funding

Medical Research Council MR/K005537/1Telethon GTB12001Wellcome Trust 098330Wellcome Trust 098330/Z/12/Z
6 · The paper itself

Abstract

Trisomy 21 (T21), Down Syndrome (DS) is the most common genetic cause of dementia and intellectual disability. Modeling DS is beginning to yield pharmaceutical therapeutic interventions for amelioration of intellectual disability, which are currently being tested in clinical trials. DS is also a unique genetic system for investigation of pathological and protective mechanisms for accelerated ageing, neurodegeneration, dementia, cancer, and other important common diseases. New drugs could be identified and disease mechanisms better understood by establishment of well-controlled cell model systems. We have developed a first nonintegration-reprogrammed isogenic human induced pluripotent stem cell (iPSC) model of DS by reprogramming the skin fibroblasts from an adult individual with constitutional mosaicism for DS and separately cloning multiple isogenic T21 and euploid (D21) iPSC lines. Our model shows a very low number of reprogramming rearrangements as assessed by a high-resolution whole genome CGH-array hybridization, and it reproduces several cellular pathologies seen in primary human DS cells, as assessed by automated high-content microscopic analysis. Early differentiation shows an imbalance of the lineage-specific stem/progenitor cell compartments: T21 causes slower proliferation of neural and faster expansion of hematopoietic lineage. T21 iPSC-derived neurons show increased production of amyloid peptide-containing material, a decrease in mitochondrial membrane potential, and an increased number and abnormal appearance of mitochondria. Finally, T21-derived neurons show significantly higher number of DNA double-strand breaks than isogenic D21 controls. Our fully isogenic system therefore opens possibilities for modeling mechanisms of developmental, accelerated ageing, and neurodegenerative pathologies caused by T21.

Indexed as

AgingAnimalsCell DifferentiationCells, CulturedDown SyndromeFibroblastsHumansInduced Pluripotent Stem CellsMitochondriaNeuronsDown syndromeNeurodegenerationNeurogenesisNeuronal differentiation

Identifiers

PMID25694335
PMCPMC4737213
OpenAlexW1608695637

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.